Back to Search
Start Over
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
- Source :
- Blood Adv
- Publication Year :
- 2021
- Publisher :
- American Society of Hematology, 2021.
-
Abstract
- Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) at a single center. Grade 3+ cytopenias occurred in 97.6% of patients within the first 28 days postinfusion, with most resolved by 6 months. Overall, 63.4% of patients received a red blood cell transfusion, 34.1% of patients received a platelet transfusion, 36.6% of patients received IV immunoglobulin, and 51.2% of patients received growth factor (granulocyte colony-stimulating factor) injections beyond the first 28 days postinfusion. Only 40% of patients had recovered detectable CD19+ B cells by 1 year, and 50% of patients had a CD4+ T-cell count
- Subjects :
- medicine.medical_specialty
Clinical Trials and Observations
medicine.medical_treatment
Antigens, CD19
Single Center
Immunotherapy, Adoptive
Gastroenterology
Immune Reconstitution
Internal medicine
medicine
Humans
Pneumocystis jirovecii
B-cell lymphoma
Biological Products
biology
business.industry
Hazard ratio
Hematology
Immunotherapy
medicine.disease
biology.organism_classification
Lymphoma
Platelet transfusion
biology.protein
Lymphoma, Large B-Cell, Diffuse
Antibody
business
Subjects
Details
- ISSN :
- 24739537 and 24739529
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- Blood Advances
- Accession number :
- edsair.doi.dedup.....4ecc4dded2ce0c2893a852f91b326bd4